An observational study in Cancer, sponsored by University of Bordeaux. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by University of Bordeaux · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This scientific study aims to better understand the fear of cancer progression and self-efficacy among people diagnosed with and treated for cancer.
The primary objective of this study is to validate two questionnaires in French among patients currently undergoing cancer treatment: one to assess fear of disease progression, and the other to assess self-efficacy in coping with cancer.
Participation involves completing an online questionnaire.
10,832 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.
This study's planned enrollment of 240 is above the median of 200 across 2,642 observational studies indexed under Neoplasms.
Browse Neoplasms studies →University of Bordeaux is the lead sponsor of 18 studies on the registry; 9 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Primary care clinic
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients hospitalized in palliative care,
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants must have been diagnosed with cancer and be currently undergoing treatment for cancer, regardless of its location or stage.
Other: No intervention
This cross-sectional study uses a single assessment to evaluate all study variables through an online questionnaire. No active intervention is performed on participants. Participation involves completing this questionnaire, which comprises the following instruments : FOP-Q-SF, FCRI Severity Scale, CBI-B 2.0, WHOQOL-BREF, and GAD-7.
Fear of progression
Questionnaire Fear of progression - Short Form (FOP-Q-SF)
Time frame: At enrollment
Fear of recurrence
Fear of Cancer Recurrence Inventory - Short Form (FCRI-SF)
Time frame: At enrollment
Self-efficacy for coping with cancer
Cancer Behavior Inventory - Brief (CBI-B 2.0)
Time frame: At enrollment
Quality of life
World Health Organisation Quality of life - Bref (WHOQOL-BREF)
Time frame: At enrollment
Anxiety
Generalized Anxiety Disorder - 7 items (GAD-7)
Time frame: At enrollment
Plan to share: No
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Nov 2026, 6 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Bordeaux